OncoMatch/Clinical Trials/NCT04523688
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
Is NCT04523688 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Autologous Dendritic Cells (DC) vaccine and Temozolomide for glioblastoma.
Treatment: Autologous Dendritic Cells (DC) vaccine · Temozolomide — Single arm, monocentric trial to assess the safety and the progression-free survival related to the combined treatment of dendritic cell vaccine loaded with autologous tumor homogenate and temozolomide in patients operated for glioblastoma and then treated with standard radiochemotherapy (according to Stupp regimen).
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: radiochemotherapy (Stupp regimen) — standard of care
Patient candidate to standard radiochemotherapy (Stupp regimen)
Cannot have received: cancer vaccine
Previous treatment with a cancer vaccine
Lab requirements
Blood counts
Demonstrate adequate organ and marrow function
Kidney function
Demonstrate adequate organ and marrow function
Liver function
Demonstrate adequate organ and marrow function
Cardiac function
normal cardiological parameters (ECG and cardiological examination); appropriate 12-lead ECG and echocardiogram
Demonstrate adequate organ and marrow function; normal cardiological parameters (ECG and cardiological examination); appropriate 12-lead ECG and echocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify